Vessels are formed during embryonic development through three distinct processes. Angiogenesis and arteriogenesis involve the remodeling of established capillary networks and arterioles, while vasculogenesis involves the differentiation of mesodermal progenitor cells called angioblasts into mature endothelial cells. Until recently, postnatal vessel development was felt to occur exclusively through angiogenesis or arteriogenesis. However, recent studies using experimental tumor and ischemia models have raised controversy regarding whether vasculogenesis occurs in postnatal vessel development, with some studies suggesting the possibility and others refuting it. Here, we summarize the process of embryonic vessel development and review studies investigating the role of postnatal vasculogenesis in vessel formation in adult ischemia and tumors. We then focus on studies in which wild-type and genetically modified vascular progenitor cells have been investigated as possible cellular therapies for tumors or ischemia. We also take note of key issues that will need to be understood about the biology of vasculogenesis before cellular therapies utilizing vascular progenitor cells can be finally taken from the bench to the bedside.
INTRODUCTION
During development, new blood vessels are formed through three distinct processes. The first is vasculogenesis, the differentiation of mesodermal progenitor cells called angioblasts into mature endothelial cells.
The second is angiogenesis, the remodeling of an established capillary network, often by sprouting of endothelial cells from preexisting vasculature to generate new capillaries. The third vessel development process is arteriogenesis, the periendothelial cell-driven growth and remodeling of the endothelium of preexisting arterioles to generate new endothelial cells, which secrete factors such as platelet-derived growth factor (PDGF) and transforming growth factor-h (TGF-h) that attract mesenchymal smooth muscle precursor cells, leading to the formation of the intima and media of new vessels. Vasculogenesis produces capillaries, arterioles, and venules; angiogenesis produces capillaries; and arteriogenesis produces arterioles. Until recently, it was thought that the generation of new blood vessels in postnatal life, as occurs in response to ischemia or during the growth of a neoplasm, was due to angiogenesis or arteriogenesis. However, recent studies using experimental tumors and models of ischemia have suggested that vasculogenesis occurs in postnatal blood vessel development. While a number of studies have identified circulating bone marrow-derived endothelial precursor cells (EPCs), the adult counterpart of embryonic angioblasts, and demonstrated a contribution of EPCs to tumor endothelium [1] [2] [3] [4] and revascularizing areas of ischemia [5] [6] [7] , others have failed to detect any bone marrow-derived tumor endothelial cells [8, 9] or bone marrow-derived endothelium in revascularizing areas of ischemia [10] .
On the basis of these studies, it appears that some, but definitely not all, experimental tumors and types of ischemia utilize vasculogenesis in generating their blood vessel endothelium, emphasizing the need to identify factors that may promote vasculogenesis. Once these factors are identified, possible therapeutic applications are numerous, including: (1) enhancing the pharmacologic ability to stimulate neovascularization after ischemia or disrupt tumor vasculature by targeting all types of vessel formation and (2) a gene therapy approach in which bone marrow or endothelial progenitor cells are utilized as cellular delivery vehicles to deliver therapeutic genes to ischemic areas or tumors.
This review starts with a summary of embryonic vessel development, an important process to understand before one can understand adult vasculogenesis. We then summarize the numerous studies investigating the relative importance of vasculogenesis versus locally derived vessels (angiogenesis or arteriogenesis) in blood vessel formation in areas of ischemia and tumors, summarize studies in which wild-type and genetically modified vascular progenitor cells were used as cellular therapies for tumors or ischemia, and present key issues that must be addressed before the full potential of cellular therapies derived from vascular progenitor cells can be tapped.
VASCULAR PROGENITORS IN THE EMBRYO
Endothelial cells arise from mesodermally derived precursor cells called angioblasts. In vitro differentiation studies and studies in zebrafish have indicated that angioblasts and blood cell (hematopoietic) precursors arise from a common mesodermally derived ancestor, the hemangioblast. Hemangioblasts begin differentiating in blood islands of the yolk sac. Cells at the perimeter of blood islands give rise to angioblasts, while cells in the center become hematopoietic precursors. Early in its development, the hemangioblast begins to express CD34 and receptor-2 for vascular endothelial growth factor (VEGFR-2, flk-1) (Fig. 1) , one of two tyrosine kinase receptors that bind vascular endothelial growth factor (VEGF), the other being VEGFR-1 (flt-1). Transgenic mice deficient in VEGFR-2/flk-1 exhibit severe defects in both hematopoietic and angioblastic lineages [11] . Fujimoto et al. found that a subset of these flk-1-positive cells begins to express GATA-1 and these GATA-1-positive cells lose the capacity to become endothelium and are restricted to erythroid and macrophage differentiation [12] . Other potential factors regulating hemangioblast differentiation include differentiation-promoting transcription factors from the homeobox gene family [13] or differentiationinhibiting transcription factors from the Id family [14] .
Angioblasts have the ability to proliferate, migrate, and differentiate into endothelial cells, but have not yet acquired mature endothelial markers such as CD31 or von Willebrand factor (vWF). Angioblasts retain flk-1 and CD34 expression from their hemangioblast precursors ( Fig. 1 ) and divide in response to VEGF, while cells committed to hematopoietic lineage downregulate flk-1 expression, and certain subsets of hematopoietic cells acquire VEGFR-1 (flt-1) expression.
Angioblasts go on to assemble into primitive vascular plexuses of veins and arteries, the process of vasculogenesis. Arterial and venous endothelial cells have recently been shown to have distinct precursors expressing distinct signaling molecules [15] . Many of these signaling molecules are also expressed in the developing nervous system, where they regulate guidance of migrating neuronal precursors and developing axons [15] . Examples included ephrin-B2 [16] , neuropilin-1 [17] , and notch3 [18] , expressed by arterial EPCs, and EphB4, the receptor for arterial ephrin-B2, expressed by venous EPCs [16] . It is unclear if differentiation into arterial versus venous EPCs occurs at the level of the angioblast or earlier in development, but the existence of molecular differences between arterial and venous endothelial precursor cells before vessel formation implies that arteries and veins establish their identity independent of blood flow and pressure.
Whether endothelial cells undergo senescence after developing from EPCs in vivo remains uncertain, although they do show aging-related phenotypes. Primary endo-thelial cultures stop proliferation and arrest permanently in G0 after a certain number of divisions. This senescence is associated with decreased expression of Id1, a negative regulator of basic helix-loop-helix transcription factors. Enforced Id1 expression delays the onset of endothelial senescence due to repression of p16 [19] .
FIG. 1.
Development of mature endothelium from a hemangioblast. Hemangioblasts differentiate into angioblasts (in blood islands in the yolk sac during embryogenesis) or endothelial precursor cells (EPCs; in the adult bone marrow) and hematopoietic precursors. In the adult, EPCs are the first cells in the endothelial lineage that are capable of migrating out of bone marrow into the circulation. EPCs can differentiate into mature endothelium. Mature endothelium secretes TGF-h, which induces PDGFR-h expression in mesenchymal smooth muscle cell (SMC) precursors, which then mature into smooth muscle cells after binding PDGF-B secreted by endothelium.
Once endothelial cells mature, they secrete TGF-h, which induces platelet-derived growth factor receptor-h (PDGFR-h) expression in mesenchymal smooth muscle precursor cells in the vicinity of the vessel being generated. PDGF-B secreted by the endothelium then attracts the PDGFR-h + smooth muscle precursor, which adheres to the endothelium and forms the media of the vessel (Fig. 1) . The smooth muscle cell supports the endothelium by secreting angiopoietin-1, which binds the Tie2 receptor on the endothelial surface.
VASCULAR PROGENITORS IN THE CIRCULATION OF ADULTS
Circulating bone marrow-derived EPCs, the adult counterpart of embryonic angioblasts, were first isolated over 15 years ago from the peripheral blood of patients with vascular trauma, septic shock, sickle cell anemia, or cancer [20] . Initial EPC studies analyzed circulating blood cells using antibodies against epitopes found on both EPCs and mature endothelial cells, such as S-endo-1 (also known as CD146 or P1H12) and junctional molecule VEcadherin (Fig. 1) .
Because of this shared antigenicity with mature endothelial cells, it was initially felt that circulating EPCs were mature endothelium that had sloughed from the vascular intima into the circulation. It was subsequently shown that when these cells isolated from circulation were exposed to angiogenic factors, they formed highly proliferative endothelial colonies, whereas circulating endothelial cells could generate endothelial monolayers with only limited proliferation capacity. In 1997, EPCs were isolated on the basis of antigens shared by mature endothelium, as well as the EPCsT hemangioblast and angioblast precursors, when Asahara et al. isolated EPCs from human peripheral blood by magnetic bead selection on the basis of their VEGFR-2 and CD34 expression [6] .
An important breakthrough came in 2000 with the identification of the first antigen expressed by EPCs but not by their precursors or mature endothelium. Adult EPCs were shown to express CD133 (formerly known as AC133), a five-transmembrane-spanning 120-kDa glycoprotein orphan receptor whose ligand or function remains unknown. CD133 is expressed on certain tumor cells such as leukemic or retinoblastoma cells, as well as certain stem or progenitor cells such as EPCs and neural stem cells. When incubated with VEGF, fibroblast growth factor-2 (FGF-2), and insulin-like growth factor, CD133 + EPCs downregulate CD133 expression and differentiate into mature adherent endothelial cells, which express endothelial-specific markers such as vWF and VE-cadherin [21] . Circulating EPCs in the adult resemble embryonic angioblasts, which are motile, anchorageindependent cells with the capacity to migrate, proliferate, and differentiate into mature endothelial cells.
Angiogenic factors VEGF and angiopoietin-1 (Ang-1) have been shown to regulate mobilization of EPCs out of bone marrow into circulation [22] . After injection of recombinant proteins or adenoviral vectors expressing VEGF or Ang-1 to elevate plasma VEGF and Ang-1, VEGF induces rapid mobilization of VEGFR-2 + EPCs into the circulation, while Ang-1 delays EPC mobilization [22] . Stem cell-mobilizing agents like VEGF induce matrix metalloproteinase-9 (MMP-9) expression in hematopoietic cells. MMP-9, in turn, cleaves and activates KitL (steel factor), permitting the transfer of EPCs and hematopoietic stem cells from a quiescent to a proliferative niche, as well as increasing the mobilization of these cells from bone marrow to circulation [23] . In addition, circulating EPCs have been detected at increased frequency in the circulation of cancer patients, and tumor volume and tumor VEGF production correlate with EPC mobilization from bone marrow into circulation [24] .
One group studied the role of h2-integrins on the surface of EPCs in EPC homing to areas of neovascularization after ischemia [25] . Adding a h2-integrin blocking antibody inhibited EPC adhesion to human umbilical vein endothelial cells. This interaction between EPCs and mature endothelium occurs when EPCs extravasate out of the circulation. A h2-integrin blocking antibody also inhibited transendothelial migration of EPCs assessed in a transwell transmigration assay. Hematopoietic progenitor cells from h2-integrin-deficient mice were less capable of homing to sites of hind-limb ischemia, and resulting neovascularization was diminished. On the other hand, preactivation of the h2-integrins expressed on EPCs by activating antibodies augmented the EPCinduced neovascularization in vivo.
One group investigated whether the high cathepsin (a type of peptidase) expression seen in EPCs relative to endothelium is a prerequisite for their invasive capacity [26] . In a hind-limb ischemia model, transgenic mice
Examples of immunohistochemistry and FACS on tumor tissue used to assess contribution of bone marrow-derived cells to tumor endothelium. We implanted a murine glioma cell line (A) intracranially or (B) subcutaneously into animals harboring bone marrow transplants from transgenic mice expressing GFP in all tissues. We sacrificed the animals 4 weeks later and assessed intracranial tumors by immunohistochemistry (A), whereas we homogenized the subcutaneous tumors into single-cell suspensions and analyzed them by FACS (B). In (A), immunohistochemistry analyzed expression of endothelial antigen vWF (red secondary) and GFP (green secondary). On the merged image, blood vessels containing bone marrow-derived endothelium stained yellow due to dual GFP and vWF expression. The percentage of vessels with marrow-derived endothelium was the percentage of total vessels seen on the red image that were yellow on the merged image. In (B), the upper right-hand corner identifies CD31 + GFP + cells, which can be measured as a percentage of the total CD31 + population (upper left + upper right). There is also a population of bone marrow-derived tumor stromal cells, which includes pericytes, in the lower right quadrant, which exhibited more green fluorescence than the CD31 + GFP + cells in the upper right quadrant, although both populations are bone marrow derived.
lacking cathepsin L, one of the most expressed cathepsins in EPCs relative to endothelium, exhibited impaired neovascularization. Mobilization of EPCs induced by hematopoietic growth factors was not impaired in cathepsin L-deficient transgenic mice, but incubation of EPCs with cathepsin L inhibitor Z-FF-FMK reduced the EPCsT invasive capacity. The authors found that cathepsin L secreted by EPCs degraded extracellular matrix. Whether pharmacologic inhibition of cathepsin L can be used to inhibit pathologic neovascularization remains to be seen.
Evidence for the existence of circulating bone marrowderived mural cell progenitors that give rise to smooth muscle cells and pericytes has been slower to accumulate, perhaps reflecting the lower frequency of such cells in the circulation. In 2001, a study using labeled bone marrow transplants confirmed the existence of a circulating bone marrow-derived mural cell progenitor [27] . A year later, mural cell progenitors were isolated by selection of human mononuclear cells in PDGF-enriched medium [28] . These mural progenitors expressed the smooth muscle cell-specific cytoskeletal proteins a-actin, myosin heavy chain, and calponin. The mural progenitors also expressed CD34, flt-1 (VEGFR-1), and flk-1 (VEGFR-2), but were negative for Tie2 expression, all suggesting a potential bone marrow angioblastic origin. Integrin-a 5 h 1 expression, which mediated adhesion to fibronectin, and greater proliferation in culture distinguished mural progenitors from EPCs [28] .
EXPERIMENTAL STUDIES OF THE CONTRIBUTION OF EPCS TO BLOOD VESSELS IN VIVO
To verify that these bone marrow-derived EPCs contribute to endothelium in newly formed vessels in areas of injury or tumor, numerous experiments have utilized bone marrow or bone marrow-derived cells detectable by one of three means: (i) the donated cells can be obtained from transgenic animals expressing a detectable antigen like green fluorescent protein (GFP) or h-galactosidase ( Fig. 2) , (ii) the donated cells can be engineered to express a detectable antigen by transduction ex vivo [29] , or (iii) the donated cells can come from a donor with a naturally occurring detectable antigen such as the Y chromosome detected after transplants of male cells into females or human antigens detected after transplants of human cells into immunodeficient mice [5, 30, 31] .
If unsorted bone marrow cells are used, these cells are injected into lethally irradiated mice, and any bone marrow-derived vessels will express the detectable antigen. If a specific subtype of bone marrow-derived cell is used, such as CD34 + cells, then the animal can be nonirradiated or sublethally irradiated prior to injection, and only a fraction of bone marrow-derived cells will express the detectable antigen. Transplantation into lethally irradiated mice would be expected to lead to a greater amount of detectable vasculogenesis than injection of cells into nonirradiated mice. The degree of marrow contribution to blood vessels is typically assessed by immunohistochemistry using an endothelial-specific antigen such as CD31 or vWF combined with the marrow-specific antigen ( Fig. 2A) . Some experiments use flow cytometry on homogenized tissue if sufficient numbers of blood vessels are present, which allows single-cell suspensions to be analyzed and prevents the misinterpretation of adjacent cells expressing different antigens as a single cell expressing dual antigens, which can happen with immunohistochemistry (Fig. 2B) . However, both immunohistochemistry and flow cytometry must be interpreted with caution given the demonstration that bone marrow-derived cells can fuse with neurons, hepatocytes, and cardiomyocytes [32] . Another variable is the time from cellular injection to ischemia or tumor formation. If the animal receives a bone marrow transplant, the transplant should precede ischemic injury or tumor formation to ensure labeling of all marrow-derived cells. If the animal receives an injection of a subset of bone marrow-derived cells, the injection can be before or after ischemia or tumor implantation depending on how long the injected cells are expected to be present in the circulation. Experiments of this nature in nonneoplastic and neoplastic models are summarized below.
Nonneoplastic Contributions of EPCs to Adult Vasculogenesis-Therapeutic Implications for Human Vasculopathies
Genetically marked EPCs incorporate into ischemic murine limbs [6, 7] and functionally populate the surface of Dacron grafts in a canine bone marrow transplantation model [33] and left ventricular assist devices [34] , facilitating the rapid formation of a nonthrombogenic vascular neointima. The degree of EPC incorporation into revascularizing ischemic areas varies (Table 1) .
EPC contribution to granulation tissue was investigated using a model in which a sponge was rubbed against murine skin 90 days after lethal irradiation and bone marrow transplantation using genetically labeled bone marrow [35] . One month after injury, in the resulting granulation tissue, approximately 10% of the endothelial cells in vessels were derived from hematopoietic progenitors, greater than the approximately 1% contribution seen in control tissue from animals that also received bone marrow transplants.
EPC contribution to revascularizing areas of ischemia was assessed in a study in which human EPCs were expanded ex vivo and injected into athymic mice 1 day after operative ligation of a femoral artery [7] . Blood-flow recovery and capillary density in the ischemic hind limb were markedly improved, and the rate of limb loss was significantly reduced. The human EPCs were subsequently labeled with a fluorescent dye, and fluorescent endothelial cells were detected in areas of hind-limb ischemia. The authors conclude that ex vivo-expanded EPCs may have utility as a strategy for therapeutic neovascularization.
After transplantation of human CD34 + EPCs into nude rats, human cells were detected in 25% of newly formed vessels in infracted myocardium [5] . In another study of myocardial ischemia, transendocardial injection of unfractionated bone marrow increased vessel formation and improved cardiac function, indicating that the newly formed vessels were functional [36] . In hind-limb ischemia, transplantation of fluorescently labeled autologous CD34 + EPCs into rabbits resulted in incorporation of labeled cells into 10% of the capillaries in ischemic limbs 4 weeks after ischemia [6] . After ex vivo expansion of human EPCs in culture for 7-10 days in the presence of angiogenic growth factors, human cells were found in 56% of the vessels of the ischemic limb [7] . Injection of unfractionated bone marrow significantly improved blood flow and increased running time on a motor-driven treadmill in rats with hind-limb ischemia [37] .
A recent study by Vasa et al. [38] reported an inverse correlation between the number of cardiovascular risk factors (including diabetes and hypertension) and the number and migratory activity of EPCs, implying that cell transplantation might be an appropriate strategy for revascularization in patients with coronary artery disease. The impaired EPC function in diabetics is consistent with in vitro findings showing that insulin plays a significant role in EPC function and differentiation [39] .
Endothelial cells are not the only bone marrow-derived cells contributing to vasculogenesis after ischemia. In one study, GFP + bone marrow was transplanted into lethally irradiated C57BL/6 mice followed 6 weeks later by induction of hind-limb ischemia [10] . One and three weeks after ischemia was induced, no GFP + endothelium or smooth muscle cells were detected, but GFP + cells costaining with CD45 and F4/80 (monocytes/macrophages), vimentin (fibroblasts), and NG2 (periendothelial pericytes) were frequently present in the adventitia of collateral arteries [10] .
Unlike embryonic vasculogenesis, adult vasculogenesis depends on inflammation. Inflammatory cells, primarily macrophages, release cytokines that stimulate vasculogenesis. In the case of ischemia, infiltrating macrophages release matrix metalloproteinase-9, which regulates capillary branching during new vessel sprouting, and the extent of revascularization correlates with the magnitude of the macrophage infiltrate [40] .
Therapies designed to stimulate vasculogenesis in patients suffering from ischemia have undergone numerous clinical trials. In one such trial, stents coated with an antibody against CD34, designed to capture circulating EPCs, were implanted into 16 patients with newly diagnosed coronary artery disease, resulting in a 6-month stent volume obstruction of 27.2% [41] , an Only studies in which the percentage of marrow-derived endothelium or vessels with a marrow contribution was quantified are included. Abbreviations used: iv, intravenous; LAD, left anterior descending coronary artery; EPC, endothelial progenitor cell; IHC, immunohistochemistry.
encouraging early result that needs confirmation in a randomized, controlled trial. A second example of a trial designed to stimulate vasculogenesis in ischemia patients is the randomized, controlled trial of bone marrow transfer to enhance ST-elevation infarct regeneration (the BOOST trial). The BOOST trial was conducted in Germany to determine the effect of intracoronary autologous bone marrow cell (BMC) transfer on left ventricular functional recovery in patients after acute myocardial infarction and successful percutaneous coronary intervention (PCI). Five days after PCI, 30 patients received optimal medical therapy, and 30 patients received optimal medical therapy plus intracoronary transfer of autologous BMCs [42] . After 6 months, the left ventricular ejection fraction increased 0.7 percentage points in the control group and 6.7 percentage points in the BMC transfer group ( P = 0.0026).
Contributions of EPCs to Tumor Vessel Formation
Tumor blood vessels are architecturally different from their normal counterparts-they are irregularly shaped, dilated, and tortuous and they can have dead ends. They are not organized into definitive venules, arterioles, and capillaries like their normal counterparts, but rather share chaotic features of all of them. Tumor reliance on vasculogenesis versus angiogenesis or arteriogenesis is likely multifactorial, with tumor type and microenvironment among the possible regulatory factors (Table 2) . Experimental tumor models such as rat mammary carcinomas and neuroblastomas do not rely on vasculogenesis and acquire blood vessels during growth in two phases. First, extremely small tumors utilize vessel co-option, whereby they take up existing blood vessels from surrounding normal tissues. Subsequently, co-opted vessels begin secreting angipoietin-2 (the natural antagonist for the angiogenic endothelial Tie2 receptor), mediating their own regression [43] and leading to tumor hypoxia, causing upregulation of factors such as VEGF, which in combination with angiopoietin-2 at the tumor periphery, triggers angiogenesis, the second phase. Endothelial cells lining existing blood vessels are activated, degrade the extracellular matrix, migrate through the matrix, and proliferate. New endothelial cells organize into hollow tubes, which ultimately form new sprouting vessels branching off the vessel from which the first endothelial cell(s) originated [44] .
In some experimental models, vasculogenesis is necessary for tumor growth. [2] . In the early phases of tumor growth, most vessels in both types of tumors were derived from transplanted bone marrow cells. By day 14, however, only 50% of the vessels in Lewis lung carcinoma contained donor cells, whereas most of the vessels in B6RV2 lymphomas contained donor cells. So the long-term dependence of a particular tumor on bone marrow-derived precursors might be dictated by additional tumor-specific factors.
Stoll et al. pooled data from a number of studies documenting EPC contribution to tumor vessels in several experimental models and developed a mathematical model quantifying the EPC contribution to tumor vessels [45] . The model predicted that during the early stages of tumor growth, EPCs make a significant contribution to tumor vessels, mediated primarily by their homing to the tumor, not by their proliferation. The model also showed that, as the tumor grew, EPCs accumulated near the tumor periphery, coincident with the location of the highest vascular density.
Other studies have found that bone marrow-derived cells become perivascular nonendothelial cells such as pericytes. While endothelial cells have been studied extensively, much less is known about the pericyte, a name (bperiQ meaning around and bcyteQ meaning cell) that denotes the cellTs periendothelial location at the abluminal aspect of microvessels. Compared to pericytes associated with normal vessels, pericytes associated with tumor vessels are loosely attached to endothelial cells, making tumor vessels leakier, which makes it more difficult to get drugs to tumors but also makes tumor vessels more susceptible to antiangiogenic agents, because pericytes secrete factors such as VEGF that enhance the viability of endothelial cells in close proximity. In one study, 5-8 weeks after bone marrow transplant, subcutaneous B16 melanoma tumors were grown for 14-21 days [46] . While no marrow-derived endothelial cells were found, there were high numbers of marrow-derived periendothelial cells that were CD11b + NG2 + , a phenotype found in pericytes. The authors caution that, given the proximity of pericytes to blood vessels, those interpreting blood vessel endothelium as being bone marrow derived using immunofluorescence may be detecting adjacent pericytes that are actually the source of the marrowderived antigen. It may still be worthwhile to study the effects of inhibiting the formation of pericytes from marrow-derived cells because pericytes are felt to be essential for the stability of the tumor microcirculation, especially in late-stage tumors [47] .
The studies described above found a wide range of bone marrow contribution to murine tumor vessels: 0% of vessels in some studies, but 50 to 98% in other The method of labeling transplanted cells varied from experiment to experiment and is not stated here. Only studies in which the percentage of marrow-derived endothelium or vessels with a marrow contribution was quantified are included. Abbreviations used: SCID, severe combined immunodeficiency; FACS, fluorescence-activated cell sorting; EPC, endothelial progenitor cell; LLC, Lewis lung carcinoma; IHC, immunohistochemistry; BMT, bone marrow transplant; VEGF, vascular endothelial growth factor; TRAMP, transgenic adenocarcinoma of the mouse prostate; PTEN, phosphatase and tensin homolog deleted on chromosome 10. studies (Table 2 ). But implanted tumors grow different from tumors that form spontaneously-implanted tumors contain a large number of cells that must immediately obtain a blood supply, while tumors originating spontaneously from a single cell over time rely initially on the blood vessels that perfused the cell of origin and have time to acquire vessels during the early phases of tumor growth. As a result, several investigations have studied vasculogenesis in transgenic mice that spontaneously form tumors, a model felt to resemble human tumors better than implanting cell lines into rodents. These studies found vasculogenic contributions in between the extremes of the experimental models described above. In one such study, Id1 À/À Id3 +/À transgenic mice were crossbred to transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, which spontaneously form prostate tumors [48] . Transplantation of wild-type bone marrow into Id-deficient TRAMP mice reduced hemorrhage in spontaneously arising poorly differentiated prostate adenocarcinomas. Bone marrowderived endothelial cells contributed to 2.6% of the vessels in well-differentiated prostate tumors and 14.2% in poorly differentiated prostate tumors, indicating increasing vasculogenesis with tumor grade in prostate tumors.
In a related study, Id1 À/À Id3 +/À mice were crossbred to PTEN +/À mice, which spontaneously form uterine carcinomas [4] . The resulting mice developed uterine carcinomas that were more hemorrhagic and necrotic than the uterine carcinomas of PTEN +/À mice. When hgalactosidase (LacZ) + marrow was transplanted into PTEN +/À or PTEN +/À Id1 À/À Id3 +/À mice, 16 or 16.5% of CD31 + vessels had LacZ + CD31 + cells in them. Thus, bone marrow-derived EPCs contribute to the neovasculature of PTEN-mutated tumors, a genotype associated with increased tumor vascularity [49] due to PTENTs ability to stimulate release of thrombospondin 1 [50] , an inhibitor of tumor neovasculature formation due to its ability to decrease numbers of circulating EPCs and EPC viability [51] .
In comparing different reports quantifying tumor vasculogenesis, it is important to keep in mind that the process is multifactorial. For example, the Lewis lung carcinoma cell line has been reported to form subcutaneous tumors with anywhere from 0.02 to 98% of the blood vessels having a marrow contribution [2, 29] . This may reflect slight differences in how long the tumors had been growing (slightly longer in the studies documenting no vasculogenesis) or the mouse strain of the host, which differed between the studies. In fact, different mouse strains vary in amounts of vasculogenesis. One study tested eight inbred mouse strains for intrinsic levels of circulating EPCs (CD13 + VEGFR-2 + CD45 À CD117 À ) and found over 30-fold variation among analyzed strains [52] . Strains with higher levels of circulating EPCs exhibited greater numbers of blood vessels in a corneal neovascular micropocket assay and in the Matrigel plug perfusion assay, although the formed blood vessels were not confirmed to be marrow-derived.
Magnetic resonance imaging (MRI) was used to visualize vasculogenesis in one study in which murine Sca1 + bone marrow cells were labeled ex vivo with MRI-detectable ferumoxides-oly-l-lysine complexes and then injected intravenously into sublethally irradiated SCID mice before (2 days) or after (2-6 days) intracranial implantation of RT2 rat glioma cells [53] . Bone marrowderived cells were seen in the intracranial tumors as hypodense areas in the tumor on spin or gradient echo sequences, although the phenotype of these bone marrowderived cells could not be ascertained from MRI and required immunohistochemistry, by which iron could be detected by Prussian blue staining. CD31 + cells that stained for Prussian blue were found, although these were not quantified.
The contribution of bone marrow-derived cells to tumor vasculature in naturally occurring human tumors was assessed in a study analyzing six tumors in six patients developing 15 months to 15 years after bone marrow transplantations from donors of the opposite sex [54] . Fluorescence in situ hybridization was performed with Xor Y-chromosome-specific probes on paraffin-embedded sections combined with antibody against vWF. The percentage of bone marrow-derived endothelial cells in the tumor vasculature averaged 4.9% and ranged from 1 (head and neck sarcoma) to 12% (lymphoma), which, interestingly, was closer to the numbers obtained in spontaneously arising tumors in transgenic mice than the zero or extremely high values obtained when implanting cell lines. The authors argue that since 2% of normal endothelium in vessels of transplant patients are marrow derived, the tumors in these six patients do not appear to enhance this process above background. However, the animal data have already shown that the process varies considerably with tumor type, time relative to transplant, and time after tumor formation. So, the finding of six tumors, with one exhibiting sixfold more marrow-derived endothelium than normal tissue, does not imply the process is insignificant in all human tumors, particularly since we do not yet know what percentage of tumor vessels must form by vasculogenesis before the process can be therapeutically targeted.
As stated above, adult vasculogenesis relies on inflammation, unlike embryonic vasculogenesis. The role of macrophages in stimulating vasculogenesis in recovering from ischemia was outlined above. In tumor vasculogenesis, tumor-infiltrating macrophages secrete VEGF and FGF-2, whose role in stimulating EPC recruitment and differentiation was outlined above, and the number of tumor-infiltrating macrophages correlates directly with tumor vascularity and inversely with prognosis in breast cancer [55] .
EXPERIMENTAL CANCER THERAPIES: DRUGS INHIBITING VASCULOGENESIS OR DELIVERY OF CELLS OR GENES TO VASCULOGENIC TUMORS
Vajkoczy et al. used embryonic endothelial progenitor cells (eEPCs) as a model of adult EPCs. One day after a single eEPC injection, 12% of tumor vessels contained eEPCs, a number that dropped to 3% after 4 days [56] . eEPC homing to the tumor vasculature was blocked by 76% using neutralizing antibodies against E-and P-selectin molecules. Whether neutralizing antibodies against E-and P-selectin block tumor vasculogenesis remains to be determined.
Angiostatin, a naturally occurring angiogenesis inhibitor derived from plasminogen and found in the circulation, was found to inhibit human EPC growth in culture by 75%, while having no effect on endothelial cell growth [57] . The authors of that study argued that angiostatin may exert its effects by inhibiting the EPC contribution to tumor vessel formation, although an in vivo demonstration of angiostatin inhibiting vasculogenesis in a vasculogenic tumor model was lacking.
Another naturally occurring angiogenesis inhibitor found in the circulation that affects EPCs is endostatin, a cleaved product of collagen XVIII. One report found that VEGF increased EPC mobilization from the bone marrow into circulation and that endostatin blocked this mobilization [58] . Endostatin was shown to increase EPC apoptosis. Again, in vivo effects of this agent on tumor vasculogenesis were not assessed.
Because VEGF increases EPC mobilization from bone marrow into circulation, the effects of the VEGF-specific antibody bevacizumab on the number of circulating EPCs in six patients with rectal adenocarcinoma was investigated [59] . The amount of CD133 + EPCs decreased in all patients, and all six patients experienced tumor regression.
Based on observations that during break periods between successive cycles of maximal cyclophosphamide chemotherapy, there can be marked mobilization of hematopoietic progenitors from the marrow into the circulation, the effect of cyclophosphamide on EPCs has been studied [60] . Tumor-bearing mice treated with the maximum tolerable cyclophosphamide dose experienced a robust EPC mobilization within a few days, while tumorbearing mice receiving metronomic (low-dose) cyclophosphamide experienced a decrease in circulating EPCs and EPC viability, suggesting that metronomic chemotherapy regimens inhibit vasculogenesis, without the side effects of higher dose regimens that target tumor cells. Protracted exposure of endothelial cells in vitro to low concentrations of several chemotherapy agents, including cyclophosphamide, caused marked expression of thrombospondin 1, a potent endogenous inhibitor of angiogenesis [51] . The antiangiogenic and antitumor effects of low-dose cyclophosphamide were lost in transgenic mice deficient in thrombospondin 1 [51] . The model of Stoll et al. predicted that cyclophosphamide inhibition of the EPC contribution to tumor vessels could cause a growth delay of 14% or 4.1 days in the time required for a tumor to grow to a radius of 1.5 mm [45] . These observations suggest that tumor regression might require targeting vasculogenesis, arteriogenesis, and angiogenesis with a combined regimen.
Another approach used EPCs as a cellular vehicle to deliver a gene encoding a prodrug-activating enzyme. In one study, primate CD34 + EPCs were genetically modified with a nonreplicative herpesvirus vector expressing herpes simplex virus thymidine kinase (HSV-TK) and the marker gene h-galactosidase but lacking other genes essential for viral replication. When injected intravenously, these EPCs homed into 2-day-old skin autografts in rhesus monkeys, and the skin autografts were rejected after ganciclovir treatment because ganciclovir was phosphorylated into toxic intracellular metabolites by transduced HSV-TK + CD34 + EPCs incorporated into the skin autografts [61] . Using flow cytometry, h-galactosidase + CD34 + cells were detected in peripheral blood and bone marrow biopsies obtained serially for 3 weeks in two animals and 6 weeks in an additional animal.
This approach was applied to a tumor model when Ferrari et al. isolated human CD34 + cells from peripheral blood, transduced them ex vivo with a retroviral vector expressing the HSV-TK transgene, and then injected the cells intravenously into sublethally irradiated SCID mice with subcutaneous or intracranial tumors [30] . Human EPCs contributed to 10-25% of subcutaneous endothelial cells by flow cytometry, and the human EPC contribution to intracranial tumor vasculature was also significant, although not quantified. Ganciclovir treatment of subcutaneous tumors formed from glioma cell lines in sublethally irradiated SCID mice that had received transduced CD34 + human cells resulted in 75% reduction of tumor volume. When B16F16 melanoma cells were injected intravenously 7 days after SCID mice received transduced C34 + human cells, a 44% reduction in lung metastases occurred after ganciclovir treatment.
In another gene delivery approach, unsorted murine bone marrow cells were transduced with a retroviral vector to express truncated soluble Flk-1 and/or GFP [1] . Six months after transplantation of this bone marrow into lethally irradiated mice, subcutaneous heterotopic neuroblastomas or subcutaneous WilmsT tumor cell lines in SCID mice were established. Bone marrow-derived cells contributed to 5% of the endothelial cells in each experimental model, with most marrow-derived endothelial cells occurring at the tumor periphery. Expression of soluble truncated VEGFR-2 (Flk-1) by the transplanted bone marrow led to 50% growth inhibition 25 days after tumor implantation in each experimental model. In a similar study, unsorted lineage-negative bone marrowderived progenitors were transduced with a retroviral vector expressing HSV-TK under the control of the endothelial-specific Tie2 promoter [29] . Bone marrow transplantation into lethally irradiated mice was performed, followed 4 to 48 weeks later by subcutaneous tumor implantation. In this experimental model, only 1 in 6000 vessels had a bone marrow contribution to endothelium. However, there were a large number of marrow-derived Tie2-expressing mononuclear cells that closely interacted with endothelial cells at the tumor periphery, implying that Tie2 was not an endothelialspecific promoter as had been suggested. Ganciclovir treatment caused significant tumor reduction with residual tumors showing reduced vascular density, indicating that these Tie2-expressing mononuclear cells were essential for tumor vessel formation.
CONCLUSION
The work described above establishes that: (1) EPCs are drawn out of the bone marrow and into the circulation by specific signals from ischemia and/or certain types of tumors; (2) EPCs are drawn out of the circulation and into ischemic areas or the tumor microcirculation by other specific signals from ischemic areas or certain tumors, where they contribute to vasculogenesis, the de novo formation of blood vessels; (3) EPCs can be targeted by specific drugs-either inhibition (desirable for tumor therapy) or stimulation (desirable for treating ischemia) can be achieved; and (4) transplantation of genetically engineered bone marrow or injection of genetically engineered EPCs can be used to deliver therapeutic genes or cells to ischemia or certain types of tumors. The stimuli used by ischemia and tumors may be similar, as tumoral hypoxia may trigger release of vasculogenesis-mediating factors via release of hypoxia inducible factor-1. But many unanswered questions remain for those seeking to understand the role of this process in blood vessel formation.
The first unanswered question is what factors regulate the ability of ischemia or tumors to form blood vessels through vasculogenesis? One set of secreted factors with effects at a long distance might enter the bloodstream and arrive at the bone marrow, where they liberate EPCs from the bone marrow and into the circulation, increasing the basal level of circulating EPCs. Then another set of secreted chemokines/cytokines acting locally within the tumor bed or ischemic tissue might interact with tissue-specific extracellular matrix laid down by each tumor type to attract EPCs chemically out of the local circulation and into the vicinity of the tumor or ischemic area. Then other factors or matrix proteins secreted by the tumor or ischemic tissue could trigger the differentiation of EPCs into tumor endothelium, or this differentiation may occur as a result of EPCs being incorporated into vessel walls.
The second set of unanswered questions relates to the biologic significance of vasculogenesis. Is vasculogenesis used when tumors are less assured of being able to rely on co-opting local vessels, such as at sites of invasion, as occurs with glioblastoma? Or does it result from an affinity for the tumor stem cell from which a tumor like lymphoma, a vasculogenic tumor, might originate, meaning vasculogenesis would decrease as the tumor grows and this tumor stem cell population becomes diluted? And what is the significance of vessels derived from vasculogenesis-are these vessels harder to destroy, meaning that even having as few as 10% of tumor vessels derived from bone marrow could be significant? What are the effects of a combined pharmacologic regimen targeting angiogenesis, vasculogenesis, and arteriogenesis versus a regimen targeting just one of these processes? Do tumors exhibit a compensatory increase in vasculogenesis or use of local vessels when one process is pharmacologically inhibited?
These questions continue to be investigated in this recently uncovered but vital field of tumor biology research, which we are hopeful will make a transition from bench to bedside in the near future.
